Dr. Kantoff on the Rationale to Evaluate VERU-111 in mCRPC

October 20, 2020
Philip W. Kantoff, MD

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Philip W. Kantoff, MD, chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care® winner for Genitourinary Cancer, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer (mCRPC).

VERU-111 is a​n oral tubulin inhibitor, says Kantoff. Taxanes​, such as docetaxel and cabazitaxel (Jevtana), are also active against tubulin​, Kantoff explains.

​Although taxanes and VERU-111 are active against tubulin, their distinct mechanisms of action are not fully defined, explains Kantoff.

Currently, ​taxanes have demonstrated modest activity in patients with mCRPC, ​although docetaxel has shown significant activity in the metastatic hormone-sensitive setting, Kantoff concludes.

Related Content:

Onclive TV | Prostate Cancer

x